Targeting the incretin system has become an important therapeutic approach for treating
type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 …

The incretin system has become an important target in the treatment of type 2 diabetes in
recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose …

Background It is estimated that 29.1 million people or 9.3% of the US population have
diabetes, which contributes to considerable medical and financial burden. Type 2 diabetes …

Incretin‐based therapies, such as the injectable glucagon‐like peptide‐1 (GLP‐1) receptor
agonists and orally administered dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have recently …

Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2
diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for
treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes …

Novel therapeutic options for type 2 diabetes mellitus based on the action of the incretin
hormone glucagon-like peptide (GLP)-1 were introduced in 2005. As injectable GLP-1 …

Glucagon-like peptide-1 receptor analogues/agonists (GLP-1RAs) are well established as
effective adjuncts to lifestyle modification in the treatment of type 2 diabetes (T2D) as …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well established as effective
treatments for patients with type 2 diabetes. GLP-1 RAs augment insulin secretion and …

Objective The role of glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of
type 2 diabetes is debated; many recent trials, which were not included in previous meta …